Evidence map›Paper›PMID 42427242›Full record

ArticleChemMedChem2026

A Priori Design, Combinatorial Synthesis, and Assessment of an Antipackaging Peptide Against Human Immunodeficiency Virus 1: Functional Role of Unnatural Trp Mimetics and Serendipitous Discovery of a Protease Inhibitor.

Jacob R Immel, Pei-Hsuan Chen, Peter McDonald, Anuradha Roy, David Johnson, Steven Bloom

Abstract read
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jacob R ImmelDepartment of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA.
Pei-Hsuan ChenDepartment of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA.
Peter McDonaldCOBRE CBID Infectious Disease Assay Development Core, University of Kansas, Lawrence, Kansas, USA.
Anuradha RoyCOBRE CBID Infectious Disease Assay Development Core, University of Kansas, Lawrence, Kansas, USA.
David JohnsonComputational Chemical Biology Core, University of Kansas, Lawrence, Kansas, USA.
Steven BloomDepartment of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA.ORCID https://orcid.org/0000-0002-4205-4459

Funding

Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
New catalytic strategies to make non-proteinogenic peptidesR35GM147169 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Steven Bloom · 2022 to 2026
$1.9M
NIGMS NIH HHS P20GM113117NIGMS NIH HHS R35GM147169
6 · The paper itself

Abstract

HIV-1 is a prevalent disease worldwide. While current therapies keep the virus at bay-suppressing viral loads and minimizing risks of transmission-viral mutations that confer drug resistance are still a significant problem. It would, therefore, be advantageous to have therapies that address viral targets that are highly conserved and critical for viral replication. One such option is ψRNA. This region of RNA serves as the recognition site for the NCp7 viral protein. The binding of NCp7 to ψRNA guides the packaging of intact viral RNA into nascent daughter virions. Thwarting this process leads to virions that incorporate nonfunctional RNAs and are not infectious. Based on prior studies, we designed, synthesized, and tested a library of nonproteinogenic tetrapeptides to target stem-loop elements of ψRNA known to interact with NCp7. Peptides incorporating aza-indole (tryptophan-like) amino acids displayed considerable anti-HIV and trophic-specific activity yet failed to inhibit packaging. Instead, our best analog (IC

Indexed as

Anti-HIV AgentsDrug DesignHIV-1HIV Protease InhibitorsPeptidesTryptophanCombinatorial Chemistry TechniquesDose-Response Relationship, DrugHumansMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipVirus ReplicationAnti-HIV AgentsHIV Protease InhibitorsPeptidesTryptophanantiretroviral peptideHuman Immunodeficiency Virus 1packagingprotease

Identifiers

PMID42427242
PMCPMC13351823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.